Skip to main content

Table 2 Efficacy of a single oral dose of Simparica Trio™ against natural nematode infections in dogs presented as veterinary patients in Europe

From: Field efficacy and safety of a novel oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against naturally acquired gastrointestinal nematode infections in dogs presented as veterinary patients in Europe and the USA

Nematode speciesSampleaTreatment groupbnEgg count per gram fecesEfficacy
Geometric mean95% CI% ReductionTest statisticc
Across all speciesPre-treatmentSimparica Trio™19393.068.4–126.3  
Post-treatmentSimparica Trio™1791.00.5–1.798.9t(17.9)= 22.11, P < 0.0001
Afox+Milb911.40.7–2.498.7t(59)= 16.49, P < 0.0001
T. canisPre-treatmentSimparica Trio™13884.558.6–121.6 
Post-treatmentSimparica Trio™1270.80.4–1.599.0t(193)= 19.97, P < 0.0001
Afox+Milb560.70.2–1.699.3t(194)= 14.29, P < 0.0001
T. leoninaPre-treatmentSimparica Trio™918.66.9–47.9 
Post-treatmentSimparica Trio™90.3− 0.2–1.298.3t(14)= 6.30, P < 0.0001
Afox+Milb70.1− 0.4–0.999.9t(14)= 9.98, P < 0.0001
A. caninumPre-treatmentSimparica Trio™5245.327.6–74.1 
Post-treatmentSimparica Trio™490.5− 0.1–1.399.0t(28.8)= 11.21, P < 0.0001
Afox+Milb281.30.3–2.897.4t(47.4)= 8.31, P < 0.0001
U. stenocephalaPre-treatmentSimparica Trio™2386.932.8–227.6 
Post-treatmentSimparica Trio™220.3− 0.5–2.399.7t(20.9)= 14.60, P < 0.0001
Afox+Milb131.80.0–6.598.3t(12)= 5.87, P < 0.0001
  1. aPre-treatment sample collected once between Day-7 and 0; post-treatment sample collected between Day 7 and 14
  2. bSingle oral administration of Simparica Trio™ on Day 0 to provide dose ranges of 1.2–2.4 mg/kg sarolaner, 24–48 µg/kg moxidectin and 5–10 mg/kg pyrantel (as pamoate salt)
  3. cTest statistic and P-value for difference (pre-treatment – post-treatment) within group
  4. Abbreviations: Afox, afoxolaner; Milb, milbemycin oxime; CI, confidence interval